NASDAQ$SIBN

SI-BONE Inc · Q4 2022 earnings

Q4 2022 earnings · · Investor relations

Briefing

SI-BONE's Q4 2022 financial results were reported, showing revenue growth and progress in strategic priorities.

SI-BONE, Inc. reported a 27% increase in worldwide revenue for Q4 2022, reaching $32.0 million. U.S. revenue increased by 28% to $30.0 million. The company's net loss was $11.2 million, or $0.32 per diluted share, and the adjusted EBITDA loss improved by 54% to $4.2 million.

  • Worldwide revenue increased by 27% to $32.0 million compared to the prior year period.
  • U.S. revenue grew by 28% to $30.0 million, driven by domestic case volumes.
  • Gross margin was 84%, impacted by lower average selling prices and higher costs.
  • Net loss improved to $11.2 million, or $0.32 per diluted share, compared to $14.5 million in the prior year period.

Headline financials

Total Revenue

$32M

Previous: $25.2M+26.6%
EPS (adj)

-$0.32

Previous: -$0.43+25.6%
Gross margin

84.0%

No prior period
Capital Expenditures

$1.66M

Previous: $1.78M-6.5%
Free Cash Flow

-$8.44M

Previous: -$14.5M+41.8%
Net Income

-$11.2M

Previous: -$14.5M+22.8%
Operating Income

-$11.3M

Previous: -$13.9M+18.7%
Gross Profit

$26.9M

Previous: $21.9M+22.9%
Cash & Equivalents

$20.7M

Previous: $63.4M-67.3%
Total Assets

$158M

Previous: $191M-17.3%
Stock-Based Comp

$5.88M

Previous: $4.34M+35.6%

Revenue & EPS history

SI-BONE · Revenue · Quarterly

$32M

Q4 2022+26.6%vs Q4 2021
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Forward guidance

SI-BONE expects 2023 worldwide revenue of approximately $124 million to $127 million, representing growth of approximately 17% to 19% compared to fiscal year 2022. SI-BONE also anticipates that gross margin will be approximately 80% for fiscal year 2023 and Adjusted EBITDA loss will continue to improve year over year in 2023.

Tailwinds

  • Expects 2023 worldwide revenue of approximately $124 million to $127 million
  • Revenue growth of approximately 17% to 19% compared to fiscal year 2022
  • Anticipates that gross margin will be approximately 80% for fiscal year 2023
  • Adjusted EBITDA loss will continue to improve year over year in 2023
  • Demand momentum continues

Headwinds

  • Remains cognizant of the early phase of re-acceleration of the U.S. business
  • Pace of international recovery
  • Ability to introduce and commercialize new products and indications
  • Ability to maintain favorable reimbursement for procedures using its products
  • Impact of any future economic weakness on the ability and desire of patients to undergo elective procedures

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2022

Historical avgQ4 2022

-1.8%

Avg return

Earnings day

-1.3%

Avg return

5 days after

+0.0%

Avg return

30 days after

40%

12 / 30 earnings

Positive

+16.2%

Q4 2022

Best reaction

-23.7%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-5.3%+15.3%+25.1%
Q4 2025-1.0%-0.6%-17.8%
Q3 2025+16.1%+11.1%+20.0%
Q1 2025+15.6%+29.8%+33.8%
Q4 2024+5.6%+3.7%-19.9%
Q3 2024-17.5%-18.8%-14.5%
Q2 2024-3.6%-5.2%+10.2%
Q1 2024+10.4%+8.0%-1.1%
Q4 2023-12.4%-15.7%-22.0%
Q3 2023-4.7%-12.4%-0.9%
Q2 2023-12.5%-9.6%-7.1%
Q1 2023+9.6%-0.3%+13.9%
Q4 2022+16.2%+19.5%+14.0%
Q3 2022-23.1%-16.4%-26.5%
Q2 2022-6.4%+0.1%+3.5%
Q1 2022-23.7%-27.6%-12.2%
Q4 2021+2.4%+3.2%+3.2%
Q3 2021-7.8%-10.9%-13.6%
Q2 2021-15.1%-18.9%-18.3%
Q1 2021-7.0%-7.5%-17.2%
Q4 2020+4.0%+6.6%+8.3%
Q3 2020+3.2%+0.5%+10.7%
Q2 2020+13.6%+17.7%+31.7%
Q1 2020+9.0%+11.9%+16.3%
Q4 2019-11.9%-21.7%-28.9%
Q3 2019-4.4%-4.5%-0.6%
Q2 2019+6.8%+10.7%+11.3%
Q1 2019-3.9%-8.1%-1.5%
Q4 2018-4.6%-3.6%-9.4%
Q3 2018-3.0%+4.8%+10.5%
Q2 2018
Q1 2018
Q4 2017
Q3 2017
Q2 2017
Q1 2017
Q1 2016
Q1 2015
Q4 2014
Q1 2014

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro